Trocoxil (37 - 47 kg)
Active substance
ATC code
Species
Dogs aged 12 months or more.
Indications
For the treatment of pain and inflammation associated with degenerative joint disease in dogs in cases where continuous treatment exceeding one month is indicated.
Dose to be administered and administration route
Oral use.
THIS IS NOT A DAILY NSAID. The dose is 2 mg mavacoxib per kg body weight given immediately before or with the dog’s main meal. Care should be taken to ensure that the tablet is ingested.
The treatment should be repeated 14 days later, thereafter the dosing interval is ONE MONTH. A treatment cycle should not exceed 7 consecutive doses (6.5 months).
|
Bodyweight (kg) |
Number and Strength of Tablets to be Administered |
||||
|
6 mg |
20 mg |
30 mg |
75 mg |
95 mg |
|
|
5-6 |
2 |
||||
|
7-10 |
1 |
||||
|
11-15 |
1 |
||||
|
16-20 |
2 |
||||
|
21-23 |
1 |
1 |
|||
|
24-30 |
2 |
||||
|
31-37 |
1 |
||||
|
38-47 |
1 |
||||
|
45-52 |
1 |
1 |
|||
|
53-62 |
1 |
1 |
|||
|
63-75 |
2 |
||||
Adverse reactions
Dogs aged 12 months or more:
|
Common (1 to 10 animals / 100 animals treated): |
Vomiting, Diarrhoea. |
|
Uncommon (1 to 10 animals / 1,000 animals treated): |
Apathy, Appetite loss. Bloody diarrhoea, Melaena. Renal disorder (degradation of renal biochemistry parameters and impaired renal function).* |
|
Rare (1 to 10 animals / 10,000 animals treated): |
Gastric ulcer, Small intestine ulcer. |
*In rare cases these adverse reactions may be fatal.
If an adverse event following the administration of Trocoxil occurs, no further tablets should be administered and general supportive therapy, as applied to clinical overdose with NSAIDs, should be applied. Particular attention should be paid to maintaining haemodynamic status.
Gastrointestinal protectants and parenteral fluids, as appropriate, may be required for animals that experienced gastrointestinal or renal adverse events. Veterinarians should be aware that clinical signs of adverse events may continue when supportive therapy (such as gastro protectants) is discontinued.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See section “Contact details” of the package leaflet.
